ArticleF1000Research2025
Hepatoprotective potential of N-acetyl cysteine in rats with phenytoin induced liver injury.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phenytoin is an anticonvulsant medication that is effective in treating various seizure disorders. It is mostly metabolized by the liver, which increases the risk of PHT-induced hepatotoxicity. Aims: This study aimed to assess the effectiveness of N-acetylcysteine (NAC) in protecting the liver from phenytoin-induced hepatotoxicity in rats. Materials and Methods: Four sets of five rats male Wistar albino rats (Rattus norvegicus) used for this study was based on their availability, well-established physiology, and long history of use in pharmacological and toxicological studies each were used for analysis. Each of the four groups received different treatments: the control group received normal saline, one group received 200 mg/kg/day of NAC, another group received 5 mg/kg/day of phenytoin, and the fourth group received 200 mg/kg/day of both phenytoin and NAC. The treatments were administered orally by gavage for 45 days. Biochemical indicators (aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total serum bilirubin (TSB)) were measured in serum after the animals were anaesthetized and the experiment ended. Histological analysis was performed on liver specimens. Results: Our investigation showed that phenytoin significantly elevated liver enzymes and total serum bilirubin compared to the control and NAC groups. The concurrent administration of NAC and phenytoin led to a notable reduction in these biomarkers, excluding ALP levels. Moreover, the group that received NAC alone did not exhibit a significant increase in the levels of these biomarkers compared with the control group. The histopathological results were in agreement with the biochemical tests. Conclusion: This study concluded that Concomitant administration of NAC and phenytoin lowered the risk of phenytoin-induced hepatotoxicity. Moreover, this study confirmed that NAC is relatively safe when administered for a relatively prolonged period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.